Market analysis of China's proprietary Chinese medicine industry in 2020: The market size has exceeded 800 billion yuan. The cardio-cerebrovascular market is relatively large.

Keywords: Traditional Chinese Medicine Sulfur Dioxide Analyzer Chinese Pharmacopoeia 2020

1. Increased health awareness of Chinese residents
After experiencing outbreaks of avian flu, swine flu, and various infectious diseases, Chinese residents pay more attention to health and are willing to spend more on medical and health products such as Chinese medicine to maintain and improve their health. The per capita annual consumption expenditure on healthcare/medical products and services in China increased from approximately RMB1,165 in 2015 to approximately RMB1902 in 2019, representing a compound annual growth rate of approximately 13.0%.

2. China's proprietary Chinese medicine market is growing rapidly
In recent years, the government has introduced a series of measures to reform the medical system, stimulating the development of China's pharmaceutical industry. The Chinese patent medicine market has experienced rapid growth between 2015 and 2019. The market size has grown from 625.2 billion yuan in 2015 to 814.9 billion yuan in 2019, with a compound annual growth rate of 6.8%.


In 2019, the output of Chinese patent medicines in my country was 2.464 million tons. As of January-September 2020, the output of Chinese patent medicines in China reached 1.584 million tons, a year-on-year decrease of 11.5%.


The market size of China's QDBS proprietary Chinese medicines (invigorating qi and blood Chinese patent pills) increased from about 51.4 billion yuan in 2014 to about 92.9 billion yuan in 2019, with a compound annual growth rate of 12.6%.

Note: The market scale growth rate in 2015 was 13.5%.
According to the China Cardiovascular Disease Report 2018, China's cardiovascular and cerebrovascular disease patients may reach 290 million, and the number of patients is estimated to continue to rise by more than 30% in the next ten years. The market size of CC Chinese patent medicine (cardiocerebral blood vessel Chinese patent medicine capsule) increased from approximately 135.9 billion yuan in 2014 to approximately 225.4 billion yuan in 2019, with a compound annual growth rate of 10.6%.


For the above data and analysis, please refer to the "China Patent Medicine Industry Market Demand and Investment Forecast Analysis Report" by the Qianzhan Industry Research Institute. At the same time, the Qianzhan Industry Research Institute provides industrial big data, industrial planning, industrial declaration, industrial park planning, and industrial investment promotion. Program.

Article link: Chemical Instrument Network
source:Chemical Instrument Network

related suggestion

share to:

keywords: the new laboratory analytical instruments, intelligent pre-processing equipment